Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 225

1.

[Current principles in the screening, diagnosis, and therapy of colorectal cancer].

Khatkov IE, Kagramanova AV, Zakharzhevskaya NB, Babikova EA, Generozov EV, Shcherbakov PL, Parfenov AI.

Ter Arkh. 2016;88(2):90-6. Review. Russian.

PMID:
27135106
2.

[THE BIOMARKERS FOR TIMELY DIAGNOSTICS OF COLORECTAL CANCER].

Sokolova EA, Boyarskikh UA, Shirshova AN, Kel AE, Filipenko ML.

Klin Lab Diagn. 2015 Dec;60(12):15-23. Review. Russian.

PMID:
27032247
3.

Colorectal Adenomas.

Strum WB.

N Engl J Med. 2016 Mar 17;374(11):1065-75. doi: 10.1056/NEJMra1513581. Review. No abstract available.

PMID:
26981936
4.

Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.

Caviglia GP, Cabianca L, Fagoonee S, Gili FM.

Biochem Med (Zagreb). 2016;26(1):114-20. doi: 10.11613/BM.2016.012.

5.

Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.

Green BB, Anderson ML, Chubak J, Fuller S, Meenan RT, Vernon SW.

Cancer. 2016 Jan 15;122(2):312-21. doi: 10.1002/cncr.29734. Epub 2015 Oct 21.

6.

[Colorectal cancer: prevention and early detection].

Kolligs FT.

Dtsch Med Wochenschr. 2015 Sep;140(19):1425-30. doi: 10.1055/s-0041-102940. Epub 2015 Sep 24. German.

PMID:
26402177
7.

Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal Cancer.

Batty CA, Cauchi M, Lourenço C, Hunter JO, Turner C.

PLoS One. 2015 Jun 18;10(6):e0130301. doi: 10.1371/journal.pone.0130301. eCollection 2015.

8.

Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.

Tinmouth J, Lansdorp-Vogelaar I, Allison JE.

Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Review.

PMID:
26041750
9.

A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.

Vasilyev S, Smirnova E, Popov D, Semenov A, Eklund C, Hendolin P, Paloheimo L, Syrjänen K.

Anticancer Res. 2015 May;35(5):2873-80.

PMID:
25964570
10.

Comparison of patient preferences for fecal immunochemical test or colonoscopy using the analytic hierarchy process.

Xu Y, Levy BT, Daly JM, Bergus GR, Dunkelberg JC.

BMC Health Serv Res. 2015 Apr 23;15:175. doi: 10.1186/s12913-015-0841-0.

11.

Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.

Kapidzic A, van der Meulen MP, Hol L, van Roon AH, Looman CW, Lansdorp-Vogelaar I, van Ballegooijen M, van Vuuren AJ, Reijerink JC, van Leerdam ME, Kuipers EJ.

Clin Gastroenterol Hepatol. 2015 Aug;13(8):1464-71.e4. doi: 10.1016/j.cgh.2015.02.023. Epub 2015 Feb 24.

PMID:
25724706
12.

Faecal occult blood testing for colorectal cancer screening: the past or the future.

Benton SC, Seaman HE, Halloran SP.

Curr Gastroenterol Rep. 2015 Feb;17(2):428. doi: 10.1007/s11894-015-0428-2. Review.

PMID:
25673567
13.

[Colorectal cancer screening based on quantitative determining of fecal hemoglobin and transferrin].

Filimonov AV, Kotlyarov EV, Bilan EV.

Vopr Onkol. 2015;61(6):994-7. Russian.

PMID:
26995994
14.

Epidemiology and screening: what's new?

Bonelli L.

Colorectal Dis. 2015 Jan;17 Suppl 1:10-4. doi: 10.1111/codi.12815. No abstract available.

PMID:
25511855
15.

Advances in Fecal Occult Blood Tests: the FIT revolution.

Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE.

Dig Dis Sci. 2015 Mar;60(3):609-22. doi: 10.1007/s10620-014-3445-3. Epub 2014 Dec 10. Review.

16.

Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan.

Sakata N, Sakata Y, Shimoda R, Sakata H, Iwakiri R, Fujimoto K, Mizuguchi M, Irie H, Shimoda Y, Noshiro H.

Hepatogastroenterology. 2014 Jul-Aug;61(133):1224-8.

PMID:
25436287
17.

Fecal hemoglobin concentration as a measure of risk to tailor colorectal cancer screening: are we there yet?

Garcia M, Milà N, Binefa G, Benito L, Gonzalo N, Moreno V.

Eur J Cancer Prev. 2015 Jul;24(4):321-7. doi: 10.1097/CEJ.0000000000000090.

PMID:
25370684
18.

[Colorectal cancer screening: a work in progress].

Bretagne JF.

Presse Med. 2014 Nov;43(11):1165-7. doi: 10.1016/j.lpm.2014.08.004. Epub 2014 Sep 26. French. No abstract available.

PMID:
25261917
19.

Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.

Chiang TH, Chuang SL, Chen SL, Chiu HM, Yen AM, Chiu SY, Fann JC, Chou CK, Lee YC, Wu MS, Chen HH.

Gastroenterology. 2014 Dec;147(6):1317-26. doi: 10.1053/j.gastro.2014.08.043. Epub 2014 Sep 6.

20.

Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.

Chausserie S, Levillain R, Puvinel J, Ferrand O, Ruiz A, Raginel T, Lantieri O, Launoy G, Guittet L.

Int J Cancer. 2015 Apr 15;136(8):1827-34. doi: 10.1002/ijc.29187. Epub 2014 Sep 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk